ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Fatigue & Fibro Fog: Could You Have a B-12 Deficiency?

How Glutathione Can Save Your Life

“Next Generation” Vitamin Provides Hope To Aging Societies Worldwide

Clinical determinants of Lyme borreliosis, babesiosis, bartonellosis, anaplasmosis, and ehrlichiosis...

Magnesium: An Invisible Deficiency That Could Be Harming Your Health

Resolved to lose weight in 2015? Here are five bad strategies to avoid

Make a New Year's resolution to manage your diabetes

Year of birth significantly changes impact of obesity-associated gene variant

Safely Burn Away Body Fat

Vitamin K1 and K2—Two Underappreciated Nutrients That Are Crucial for Health

 
Print Page
Email Article

ViroPharma Drug Gets a 2nd Shot at Approval: Pleconaril

  [ 71 votes ]   [ Discuss This Article ]
www.ProHealth.com • January 5, 2004


INDUSTRY WRAPUPS

Biotech

John George

Exton-based ViroPharma Inc., which shelved its experimental treatment for the common cold after it was rejected by Food and Drug Administration early last year, has entered into a new deal for Pleconaril with Schering-Plough Corp. of Kenilworth, N.J.

The two companies entered into an option agreement that could result in Schering-Plough receiving a license for ViroPharma's intranasal formulation of its antiviral compound Pleconaril as a treatment of the common cold in the United States and Canada.

Under terms of the agreement, Schering-Plough will pay ViroPharma an up-front option fee of $3 million. ViroPharma will then conduct a series of clinical studies designed to evaluate the antiviral activity, safety and other performance characteristics of the intranasal Pleconaril formulation.

Results from the studies are expected to be available in mid-2004.

Based on its assessment of the product's performance in the characterization studies, Schering-Plough will then have the option to trigger a full license agreement with ViroPharma, under which it would assume responsibility for all future development and commercialization of intranasal Pleconaril domestically and in Canada.

If Schering-Plough exercises its option, ViroPharma will receive an initial license fee of $10 million and Schering-Plough will buy ViroPharma's existing inventory of bulk drug substance for Pleconaril for an additional undisclosed fee. ViroPharma also would be eligible to receive additional milestone payments if it achieves certain targeted, but unspecified, events as well as royalties on Schering-Plough's sales of intranasal Pleconaril in the licensed territories.

"We are delighted that we've entered into this agreement with Schering-Plough," said Mark McKinlay, ViroPharma's vice president of research and development. "We hope to demonstrate that this formulation can deliver significantly more drug to the site of active common cold infections than the oral formulation, while limiting its systemic exposure and minimizing the risk of drug interactions."

The FDA rejected a tablet formulation of Pleconaril in March 2002 citing safety concerns tied to the drug's potential adverse interactions with other drugs, such as birth control pills and AIDS medicine. An FDA advisory committee also said it was concerned the widespread use of Pleconaril had the potential to yield new drug-resistant viruses.

Source: Philadelphia Business Journal.



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Why Berries Offer a Rainbow of Health Benefits Why Berries Offer a Rainbow of Health Benefits
Protecting Our Eyes Against Time-Induced Damage Protecting Our Eyes Against Time-Induced Damage
Live Longer: Groundbreaking Research on Omega-3s Live Longer: Groundbreaking Research on Omega-3s
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing